Patents by Inventor Philip John Hogan

Philip John Hogan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220033377
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: November 2, 2020
    Publication date: February 3, 2022
    Applicant: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Publication number: 20190263782
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: May 8, 2019
    Publication date: August 29, 2019
    Applicant: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Patent number: 10344015
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilizing said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: July 9, 2019
    Assignee: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Publication number: 20180118716
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 3, 2018
    Applicant: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Patent number: 9815816
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilizing said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: November 14, 2017
    Assignee: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Publication number: 20160185754
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: July 22, 2015
    Publication date: June 30, 2016
    Applicant: ASTRAZENECA AB
    Inventors: Jorgen BLIXT, Michael David GOLDEN, Philip John HOGAN, David Michael Glanville MARTIN, Francis Joseph MONTGOMERY, Zakariya PATEL, John David PITTAM, George Joseph SEPENDA, Christopher John SQUIRE, Nicholas Cartwright Alexander WRIGHT
  • Publication number: 20140378684
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Jorgen BLIXT, Michael David GOLDEN, Philip John HOGAN, David Michael Glanville MARTIN, Francis Joseph MONTGOMERY, Zakariya PATEL, John David PITTAM, George Joseph SEPENDA, Christopher John SQUIRE, Nicholas Cartwright Alexander WRIGHT
  • Patent number: 8865899
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: October 21, 2014
    Assignee: AstraZeneca AB
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Patent number: 8163926
    Abstract: The present invention relates to a process for the manufacture of a compound of the Formula IIa: wherein R is a suitable sulphonate ester; from a (C1-C6)alkyl-4-piperidinecarboxylate compound of the Formula III:
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: April 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Publication number: 20120095229
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: December 7, 2011
    Publication date: April 19, 2012
    Inventors: Jorgen BLIXT, Michael David GOLDEN, Philip John HOGAN, David Michael Glanville MARTIN, Francis Joseph MONTGOMERY, Zakariya PATEL, John David PITTAM, George Joseph SEPENDA, Christopher John SQUIRE, Nicholas Cartwright Alexander WRIGHT
  • Publication number: 20100094010
    Abstract: Processes for preparing compounds of Formula I and IV are described.
    Type: Application
    Filed: October 16, 2009
    Publication date: April 15, 2010
    Applicant: AstraZeneca AB
    Inventors: Margaret Anne Butlin, Roger John Butlin, Philip John Hogan, Andreas Meudt
  • Patent number: 7626020
    Abstract: The invention relates to compounds such as where P is a nitrogen-protecting group, and to processes for preparing these compounds.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: December 1, 2009
    Assignee: AstraZeneca AB
    Inventors: Margaret Anne Butlin, Roger John Butlin, Philip John Hogan, Andreas Meudt
  • Publication number: 20090203905
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: September 27, 2006
    Publication date: August 13, 2009
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joeph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Publication number: 20080161565
    Abstract: Process for preparing compounds of Formula (I); and (IV); are described.
    Type: Application
    Filed: February 17, 2005
    Publication date: July 3, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Margaret Anne Butlin, Roger John Butlin, Philip John Hogan, Andreas Meudt
  • Patent number: 6943254
    Abstract: A process for the manufacture of: wherein R is (1-4C)alkyl, carboxyl(1-4C)alkyl or 1,3,4-oxadiazol-2-yl comprises: (a) reaction of the diazonium salt of 3-amino-2-chloropyridine with thionyl chloride in water and an electron transfer catalyst; (b) reaction with isobutyl-(3-methoxy-5-methylpyrazin-2-yl)carbamate and an alkali metal hydride in inert solvent; and (I) where R is (1-4C)alkyl, carboxy(1-4C)alkyl: (c) reaction with a boronic acid: (or an anhydride or ester therof) in the presence of a base and a palladium or nickel catalyst in solvent; and removal of the isobutoxy carbonyl group; or (ii) where R is 1,3,4-oxadiazol-2-yl (c) reaction with 4-methoxycarbonylphenylboronic acid (or an anhydride or ester thereof) with a source fluoride ion under aqueous conditions; (d) removal of the isobutoxycarbonyl protecting group; (e) conversion of the methyl ester group to the hydrazide; and (f) conversion to a 1,3,4-oxadiazol-2-yl moiety.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: September 13, 2005
    Assignee: Astrazeneca UK Limited
    Inventor: Philip John Hogan
  • Publication number: 20030162973
    Abstract: A process is described for the manufacture of a pyridinesulfonyl chloride or a benzenesulfonyl chloride in which the benzene ring bears one or more electron-withdrawing groups, the process comprising reacting a diazonium salt of an aminopyridine or aminobenzene in which the benzene ring bears one or more electron withdrawing groups with a mixture of thionyl chloride in water, in the presence of an electron transfer catalyst.
    Type: Application
    Filed: January 22, 2003
    Publication date: August 28, 2003
    Inventor: Philip John Hogan
  • Patent number: 6531605
    Abstract: A process is described for the manufacture of a pyridinesulfonyl chloride or a benzenesulfonyl chloride in which the benzene ring bears one or more electron-withdrawing groups, the process comprising reacting a diazonium salt of an aminopyridine or aminobenzene in which the benzene ring bears one or more electron withdrawing groups with a mixture of thionyl chloride in water, in the presence of an electron transfer catalyst.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: March 11, 2003
    Assignee: Zeneca Limited
    Inventor: Philip John Hogan
  • Patent number: 4102915
    Abstract: Process for the dimerization of ACN to substantially linear C.sub.6 dimers using organic phosphinites or phosphonites as catalyst, in the presence of a proton-donating solvent and optionally a hydrocarbon co-solvent, the ACN and solvent(s) being dry and at least one of the solvents having a boiling point higher than ACN and being capable of rapid phase separation with respect to the dimeric products. Enables the unreacted ACN to be removed by distillation and the solvent(s) and product to be readily separated. Preferably the catalyst partitions in favor of the solvent phase.
    Type: Grant
    Filed: May 3, 1977
    Date of Patent: July 25, 1978
    Assignee: Imperial Chemical Industries Limited
    Inventors: James Robert Jennings, Philip John Hogan